المؤلفون: Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD

المصدر: JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100525- (2023)

مصطلحات موضوعية: AXL, Drug resistance, EGFR tyrosine kinase inhibitor, Heterogeneity, Non–small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364323000644; https://doaj.org/toc/2666-3643

URL الوصول: https://doaj.org/article/27b3e58854a34814b01a239b63d7e6ea